Reverse vaccinology--in search of a genome-derived meningococcal vaccine.
Although significant advances have been made toward the control of bacterial meningitis in children with the development of capsular polysaccharide protein conjugate vaccines, this approach has proven problematic for the serogroup B meningococcus. Non-capsular vaccines based upon outer membrane vesicles of Neisseria meningitidis have been useful in control of clonal serogroup B outbreaks, although due to variability of PorA, these vaccines may be less useful in control of endemic disease. Genome-based vaccine discovery was evaluated in an attempt to produce a candidate capable of conferring a broadly protective vaccine against a diversity of meningococcal B strains.
Danzig
Lisa
L
Clinical Research and Medical Affairs, Chiron Vaccines, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. lisa_danzig@chiron.com
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D016680:Genome, Bacterial; D006801:Humans; D008589:Meningococcal Infections / Q000382:microbiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000235:genetics* / Q000276:immunology; D051379:Mice; D038541:Neisseria meningitidis, Serogroup B / Q000235:genetics* / Q000276:immunology; D014614:Vaccines, Synthetic
D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines; D014614:Vaccines, Synthetic